论文部分内容阅读
目的 :探讨美罗华联合 CEOP方案治疗复发性非霍奇金淋巴瘤 (NHL)的疗效及安全性。方法 :2 3例复发的 B细胞 NHL 患者 ,其中 6例接受美罗华联合 CEOP方案治疗为治疗组 ;17例接受联合化疗为对照组 ;实验组患者接受 4～ 6周期美罗华 +CEOP方案治疗 ,每 1周期 2 1天 ,于每 1周期的第 1天给予美罗华 (375 m g/ m2 )静脉滴注 ,第 3天开始 CEOP方案化疗 ;对照组患者在接受 CEOP方案 (同上 )基础上加用博莱霉素 (10 m g/ m2 )、依托泊苷 (6 0 m g/ m2 )或卡氮芥 (80 mg/ m2 ) ,治疗周期为 4～ 6周期 ,每 1周期 2 1天。结果 :治疗组完全缓解率 (CR) 83.3% ,平均缓解时间 (16 .2±4 .6 )月 ;对照组完全缓解率 (CR) 2 3.5 % ,平均缓解时间 (4 .2 5± 2 .5 )月。表明接受美罗华联合 CEOP方案治疗组其完全缓解率及缓解时间明显高于对照组 (P<0 .0 5 )。结论 :美罗华联合 CEOP方案 ,可使复发性非霍奇金淋巴瘤患者再次获得较好疗效 ,且化疗药物的毒副作用未见增加
Objective: To investigate the efficacy and safety of rituximab in combination with CEOP in the treatment of recurrent non-Hodgkin’s lymphoma (NHL). METHODS: Twenty-three patients with relapsed B-cell NHL were enrolled. Six of them received rituximab plus CEOP regimen as treatment group, 17 received combination chemotherapy as control group, and four to six cycles of rituximab plus CEOP regimen received 1 Periodicity was 21 days. Rituximab (375 mg / m2) was given on the first day of every cycle and CEOP regimen was started on the third day. Patients in the control group received the CEOP regimen (ibid) (10 mg / m 2), etoposide (60 mg / m 2) or carmustine (80 mg / m 2) for a period of 4 to 6 cycles and 21 days for each cycle. Results: The complete remission rate (CR) was 83.3% in the treatment group and the average remission time was (16.2 ± 4.66) months in the treatment group. The complete remission rate (CR) in the control group was 3.5% and the average remission time was (4.2 ± 2. May. Show that the rituximab combined with CEOP regimen treatment group was significantly higher than the complete remission rate and remission time was significantly higher (P <0. 05). Conclusion: The combination of rituximab and CEOP regimen can make patients with recurrent non-Hodgkin’s lymphoma obtain better curative effect again, and the side effects of chemotherapy drugs have not increased